Have we reached peak pharma, do we own our DNA, and will adding new bases to DNA improve on nature? Get ready for 2018.
Data is at the heart of applicable genomics. As the volume and depth of genomic data grows, bioinformaticians are translating the data into interpretable patterns leading to new biological insight.
Biopharma, research- and healthcare facilities are getting more and more interested in genomics data. A fresh example is the $58 million financing round DNAnexus just completed.
DNAnexus announce equity investment to support it’s continued expansion in the clinical trials market, as well as the deployment of its Translational Informatics Suite.
Thanks to their vertical solution, no one will need to guess who owns and has access to their genetic data.
Colin’s lab processes about 350,000 samples a year in order to generate ~800,000 genotypes on very complex genetic models, we’ve talked to him ahead of the Festival.
Several individual investors from Illumina have invested in an open-source genomics database that uses the same technology employed by Bitcoin.
Christmas shoppers in search of a thoughtful gift that “is personal and says a lot” about the recipient may have just outdone themselves.
Recent studies have started to shed new light on how wrong assumptions are about the relationship between race and skin colour.
Privacy concerns keep most patients from signing up to electronically share their medical records with healthcare providers, according to new study.
If you go to any meetings on precision medicine, you’ll have noticed the increasing amount of interest in artificial intelligence (AI).
“We Need to be Able to Handle Large Scale Datasets to Prepare for This ‘Big Data’ Era” – Mark Gerstein
Mark Gerstein, PhD, gives us some inside information on applying computational approaches to problems in molecular biology.
The three big players in the world of cloud computing released their quarterly earnings this week, and it’s clear who’s speeding ahead.